SOSV GP & HAX Managing Director Duncan Turner was named one of Fortune’s top 13 seed stage climate tech VCs to watch. Fortune noted how Turner “uses his design engineering background to help climate tech founders get their product to market—a core skill that can be especially challenging for founders when the market constitutes a […]

SOSV Founder & Managing General Partner Sean O’Sullivan recently sat down with Bloomberg to discuss his storied career in climate tech and share his vision for the future of the all-important category. O’Sullivan has “quietly been one of the leading investors in the technology that could redefine what we eat, what we wear, how we […]

UPSIDE Foods has had no shortage of incredible milestones lately: following landmark regulatory approvals by the FDA & USDA, the company recently partnered with San Francisco’s Bar Crenn to make its cultivated chicken commercially available (snag a coveted reservation to try it if you can!), and last week announced its first commercial-scale plant, dubbed Rubicon, […]

Congratulations to the three SOSV portfolio companies that made the Top 20 at TechCrunch Disrupt Battlefield 2023! Take a look at the amazing innovations in human & planetary health they’re currently working on: 🌾 Brendan Collins and the team at Avalo (IndieBio) are betting the company’s AI can speed up the creation of climate-resistant crops—a crucial technology amid increasingly extreme weather […]

At SOSV’s annual general meeting last month, Po Bronson sat down with CEO Marcel Frenkel, PhD, of Ten63 Therapeutics (IndieBio 2019) to discuss the company’s latest milestones and work with AI. Frenkel shared how Ten63’s BEYOND platform “combines physics and AI in hyper-efficient search algorithms” to push the boundaries of computational drug discovery. In short, […]

In a challenging funding climate with total deal flow and valuation down, IndieBio has continued to invest aggressively in deep tech that is paving the way for a healthier future—both for humanity and the planet. As a result of this strategy, we’re excited to announce that both of SOSV’s IndieBio programs debuted their latest cohorts. […]

Pitchbook’s analyst team recently published a report entitled “Quantifying the success of YC and the largest accelerators.” SOSV was one of the five firms mentioned in the analysis, along with Y Combinator, TechStars, Global 500, and MassChallenge. The report looks at performance indices such as aggregate valuations, capital raised, and unicorns produced, among others.  We […]

“There is a day coming where everyone on the planet will be touched by SOSV companies, every day,” SOSV Managing General Partner Sean O’Sullivan said in his opening remarks at the top of SOSV’s 2023 Annual General Meeting in New York City on June 1. “It’ll be in the clothes they wear, the food they […]

Ten63 Therapeutics raised $15.9 million in Series A funding to advance and expand its internal pipeline of first-in-class small molecules inhibiting high-impact, but thus far undruggable, cancer targets. Despite advances in drug discovery, 80% of the proteins in the human body remain evasive, and some of these so-called “undruggable” proteins are believed to be major […]

In the US, an estimated 800,000 people per year have a stroke, and nearly half will experience some form of long-term paralysis as a result of permanent damage to the brain’s ability to send signals to muscles. Reach Neuro (IBSF 13) directly restores a patient’s ability to control movement post-stroke, not only giving immediate relief, […]

At SOSV, one of our core missions is the advancement of human health, and over the past decade or more we’ve pursued that mission in fields as varied as cancer therapeutics, CRISPR diagnostic platforms, assistive robotics, and remote healthcare, to name a few. More than 200 companies in our 1000+ company portfolio focus on health, and recently we sat down to rank our top 100, based on current as well as expected performance. The result is our first annual SOSV Human Health 100, which is presented below.

SOSV is sponsoring a matchup for investors and founders in the human health category.